Drug discontinuation: Insulin Glargine-aglr Injection (REZVOGLAR KWIKPEN)
FDA lists 1 presentation as To Be Discontinued. Companies: Eli Lilly and Co..
- Published by source
- 2026-09-01
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Eli Lilly and Co.
- Products
- Insulin Glargine-aglr Injection REZVOGLAR KWIKPEN
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-09-01
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1012 | new | 2026-10-22 | 4642ddae84d5…485fbb | c5a9b9050be6…035cdb |
Chain head: #1094 edf3be25ec2e…478842